

#18/12  
01-25-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NI *et al.*

Appl. No. 09/340,690

Filed: June 29, 1999

For: **Human Tumor Necrosis Factor  
Receptor-Like 2**

Art Unit: 1646

Examiner: Kemmerer, E.

Atty. Docket: 1488.0770007/EKS/PAJ



**Fourth Supplemental Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Information Disclosure Statement filed on November 28, 2000 in connection with the above-captioned application. A copy of the document is also provided.

Applicants also point out to the Examiner that Document Number AG1, U.S. Application No. 08/509,024, which was cited in Applicants' First Supplemental Information Disclosure Statement has issued into U.S. Patent No. 6,291,207.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search

has been made, or that information more material to the examination of the present patent application does not exist.

This Fourth Supplemental Information Disclosure Statement is being filed before the payment of the issue fee and is accompanied by a statement under 37 C.F.R. § 1.97(e)(2) and the fee set forth in 37 C.F.R. § 1.17(p).

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Peter A. Jackman  
Attorney for Applicants  
Registration No. 45,986

Date: Jan 16, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1488.0770007

APPLICATION NO.  
09/340,690

APPLICANT  
NI *et al.*

FILING DATE  
June 29, 1999

GROUP  
1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA1						
AB1						
AC1						
AD1						
AE1						
AF1						
AG1						
AH1						
AI1	6,303,336	10/16/01	Spear <i>et al.</i>	435	69.1	June 15, 1999
AJ1						
AK1						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL1						Yes No
AM1						Yes No
AN1						Yes No
AO1						Yes No
AP1						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	
AS	1	
AT	1	

EXAMINER *Elizabeth C. Kemmer*

DATE CONSIDERED *2/11/02*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.